A pharmacist-run smoking cessation program

Canadian Journal of Diabetes

Volumn 30, Issue 4, 2006, Pages 406-410

  Halapy, Henry ^a   MacCallum, Lori ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Cardiovascular disease; Chronic kidney disease; Pharmacist; Smoking cessation; Stages of change theory

Indexed keywords

AMFEBUTAMONE; NICOTINE GUM; NICOTINE PATCH;

ADULT; AMBULATORY MONITORING; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CONTROLLED STUDY; DIABETES MELLITUS; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; PATIENT COUNSELING; PHARMACIST; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; SMOKING CESSATION; SMOKING CESSATION PROGRAM; TOBACCO DEPENDENCE;

EID: 33845659891     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-2671(06)04009-3     Document Type: Article

References (14)

1. Health Canada Website.Available at: http://www.hc-sc.gc.ca/ hl-vs/pubs/tobac-tabac/ctums-esutc-2005/wave-phase-1_summary-sommaire_e.html. Data collected February to December 2003.
2. Barrett-Connor E, Pyorala K. Long-term complications: Diabetes, coronary heart disease, stroke and lower extremity arterial disease. In: Ekoé J-M, Zimmet P, Williams R, eds. The Epidemiology of Diabetes Mellitus: An International Perspective. Chichester, UK: John Wiley & Sons, Ltd.; 2001:301-319.
3. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(suppl):S112-S119.
4. The Tobacco Use and Dependence Clinical Practice Guidelines Panel, Staff, and Consortium Representatives. A clinical practice guideline for treating tobacco use and dependence. JAMA. 2000;283:3244-3254.
5. Rohren CD, Croghan IT. Predicting smoking cessation outcome in a medical center from stage of readiness: contemplation versus action. Prev Med. 1994;23:335-344.
6. Fagerstrom KE, Schneider NG. Measuring nicotine dependence: a review of the Fagerstrom tolerance questionnaire. J Behav Med. 1989;12:159-182.
7. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337:1195-1202.
8. Tonnesen P, Mikkelsen KL. Smoking cessation with four nicotine replacement regimes in a lung clinic. Eur Respir J. 2000; 16:717-722.
9. Baluch W. Pharmacists' role in a smoking-cessation program at a health maintenance organization. Am J Health Syst Pharm. 1995;52:287-293.
10. Gauen SE, Lee NL. Pharmacists' role in a smoking-cessation program at a managed health care organization. Am J Health Syst Pharm. 1995;52:294-296.
11. Roth MT, Andrus MR, Westman EC. Outcomes from an outpatient smoking-cessation clinic. Pharmacotherapy. 2005;25: 279-288.
12. Roth MT, Westman EC. Use of bupropion SR in a pharmacist-managed outpatient smoking-cessation program. Pharmacotherapy. 2001;21:636-641.
13. Zillich AJ, Ryan M, Adams A, et al. Effectiveness of a pharmacist-based smoking-cessation program and its impact on quality of life. Pharmacotherapy. 2002;22:759-765.
14. Sinclair HK, Bond CM, Stead LF. Community pharmacy personnel interventions for smoking-cessation. Cochrane Database Syst Rev. 2004:CD003698.